Insider filing
Traded Feb 2 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 8, 2026 · Filed Jan 9, 2026
Filing box checked: sold under a Rule 10b5-1 plan. Sales can have many reasons; shown without inference.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
56 days after results of Nov 13, 2025, 76 days before results of Mar 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $2.62 on Jan 8, 2026, 37% above its 52-week low and 58% below its high, after a 30% drop over the previous 30 trading days
52-week range $1.91 (Dec 31, 2025) to $6.31 (Apr 30, 2025), 16% of the way up, from 249 adjusted closes. 30 trading days earlier: $3.75 on Nov 24, 2025. Describes the past only, not a forecast
RSI 46, 47% under its 200-day average, 24% under its 50-day average, 58% below the 52-week high, 20-day volatility 117% a year, against the S&P 500: −22 points over 1 month, −56 points over 3 months, −66 points over 6 months
From the adjusted closes up to Jan 8, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +16.2% | −2.5% | +18.7% |
| 30 days | −24.7% | −0.5% | −24.2% |
| 90 days | −20.6% | −1.3% | −19.4% |
| 180 days | −17.0% | +7.8% | −24.8% |
Past results only. Not a forecast.
Insider filing
Traded Feb 2 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Randall Moreadith (Chief Scientific Officer) sold ~$20K of Serina Therapeutics
Planned saleInsider filing
Traded Feb 2 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.